Gland Pharma Approves Internal Corporate Restructuring to Direct US Subsidiary Ownership
Gland Pharma Ltd 路 Others (Uncategorized) 路 13 Sept 2026, 10:02 pm
Gland Pharma Approves Internal Corporate Restructuring to Direct US Subsidiary Ownership Gland Pharma Limited's Board approved the 100% equity acquisition of step-down subsidiary Gland Pharma USA Inc. from Gland Pharma International Pte. Ltd. for a cash consideration of USD 5,01,208. The transaction converts Gland US into a direct wholly-owned subsidiary to remove corporate layers and streamline operations, with no material business impact. Incorporated in Mar'22 for pharma marketing and distribution, Gland US posted FY26 turnover of Nil (FY25: USD 87,342; FY24: USD 4,83,808). The transaction is slated for completion by 31st Oct'26.
Original exchange filing (PDF)
More announcements from Gland Pharma Ltd
- Schedule of Investor Meet Intimation 路 17 Nov 2026
- Allotment of 3739 Equity Shares on exercise of ESOPs 路 16 Nov 2026
- Grant of Options to Purchase Securities 路 16 Nov 2026
- Q2FY27 Earnings Call Transcript 路 12 Nov 2026
- Gland Pharma Limited has issued Corporate Guarantee on behalf of Phixen SAS, wholly owned step down subsidiary of the Company 路 12 Nov 2026
- Appointment of Mr. Xiao Le as Chief Investment Officer at Gland Pharma International Pte. Ltd, wholly owned subsidiary of Gland Pharma Limited, effective November 09, 2026 路 09 Nov 2026
- Q2FY27 Earnings Call Recording 路 07 Nov 2026
- Q2Fy27 Investors presentation 路 06 Nov 2026
